{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T21:26:09Z","timestamp":1726435569473},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>We report a case of dermatomyositis associated with rheumatoid arthritis, Hashimoto thyroiditis, and diabetes mellitus responsive only to combination of rituximab with mycophenolate. A 42-year-old woman presented with proximal muscle weakness, myalgias, fever, night sweats, and shortness of breath. Creatinine kinase was 8155 IU\/L, and muscle biopsy was diagnostic of dermatomyositis. She was started on glucocorticoids; her systemic symptoms improved, but her muscle weakness persisted. She was serially treated with intravenous immunoglobulin, azathioprine, and mycophenolate mofetil without improvement in her weakness. She responded dramatically to combination therapy with rituximab and mycophenolate, with improvement in strength and normalization of creatinine kinase. She has been well controlled on rituximab infusion every 6 months and maintenance mycophenolate mofetil.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cnd.0b013e318221259d","type":"journal-article","created":{"date-parts":[[2011,11,19]],"date-time":"2011-11-19T09:23:03Z","timestamp":1321694583000},"page":"63-67","update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Rituximab and Mycophenolate Combination Therapy in Refractory Dermatomyositis With Multiple Autoimmune Disorders"],"prefix":"10.1097","volume":"13","author":[{"given":"Nicholas","family":"Parziale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan C","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine B","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayashri","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20240808","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/art.1780261208","article-title":"Mortality from polymyositis and dermatomyositis in the United States, 1968-1978.","volume":"26","author":"Hochberg","year":"1983","journal-title":"Arthritis Rheum"},{"key":"R2-1-20240808","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11926-002-0087-9","article-title":"Malignancy in patients with inflammatory myopathy.","volume":"4","author":"Buchbinder","year":"2002","journal-title":"Curr Rheumatol Rep"},{"key":"R3-1-20240808","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"R4-1-20240808","first-page":"S53","article-title":"Randomized double blind trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy.","volume":"199","author":"Miller","year":"2002","journal-title":"J Neurol Sci"},{"key":"R5-1-20240808","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00431-004-1497-7","article-title":"Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A.","volume":"163","author":"Yamada","year":"2004","journal-title":"Eur J Pediatr"},{"key":"R6-1-20240808","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000051674","article-title":"Mycophenolate mofetil for dermatomyositis.","volume":"202","author":"Tausche","year":"2001","journal-title":"Dermatology"},{"key":"R7-1-20240808","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/030097400750001897","article-title":"Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis.","volume":"29","author":"Vencovsky","year":"2000","journal-title":"Scand J Rheumatol"},{"key":"R8-1-20240808","first-page":"213","article-title":"Polymyositis-dermatomyositis: 25 years of follow-up of 50 patients disease course, treatment, prognostic factors.","volume":"22","author":"Chwalinska-Sadowska","year":"1990","journal-title":"Mater Med Pol"},{"key":"R9-1-20240808","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2005.048744","article-title":"Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.","volume":"65","author":"Efthimiou","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R10-1-20240808","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases.","volume":"9","author":"Gurcan","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"R11-1-20240808","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study.","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R12-1-20240808","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/acr.20219","article-title":"Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series.","volume":"62","author":"Valiyil","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R13-1-20240808","first-page":"3844","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM)The RIM Study.","volume":"62","author":"Oddis","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R14-1-20240808","first-page":"1542","article-title":"Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases.","volume":"27","author":"Gelber","year":"2000","journal-title":"J Rheumatol"},{"key":"R15-1-20240808","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/mus.10026","article-title":"Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome.","volume":"25","author":"Schneider","year":"2002","journal-title":"Muscle Nerve"},{"key":"R16-1-20240808","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/rheumatology\/keh499","article-title":"Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy.","volume":"44","author":"Majithia","year":"2005","journal-title":"Rheumatology"},{"key":"R17-1-20240808","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archderm.142.1.65","article-title":"Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis.","volume":"142","author":"Edge","year":"2006","journal-title":"Arch Dermatol"},{"key":"R18-1-20240808","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.wnl.0000208416.32471.c0","article-title":"Mycophenolate mofetil in dermatomyositis: is it safe?","volume":"66","author":"Rowin","year":"2006","journal-title":"Neurology"},{"key":"R19-1-20240808","first-page":"1021","article-title":"Rituximab as therapy for refractory polymyositis and dermatomyositis.","volume":"33","author":"Noss","year":"2006","journal-title":"J Rheumatol"},{"issue":"pt 1","key":"R20-1-20240808","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"key":"R21-1-20240808","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/mus.20543","article-title":"Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases.","volume":"34","author":"Schneider-Gold","year":"2006","journal-title":"Muscle Nerve"},{"key":"R22-1-20240808","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood-2006-01-0329","article-title":"Inhibition of CD4+ CD25+ regulatory T cell function by calcineurin dependent interleukin-2 production.","volume":"108","author":"Zeiser","year":"2006","journal-title":"Blood"},{"key":"R23-1-20240808","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1093\/ndt\/gfp336","article-title":"Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.","volume":"24","author":"Pepper","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R24-1-20240808","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1093\/ndt\/gfp002","article-title":"Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study.","volume":"24","author":"Boletis","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R25-1-20240808","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.autrev.2010.08.012","article-title":"The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus.","volume":"10","author":"Galarza-Maldonado","year":"2010","journal-title":"Autoimmun Rev"},{"key":"R26-1-20240808","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2165\/11537510-000000000-00000","article-title":"Progressive multifocal leukoencephalopathy and newer biological agent.","volume":"33","author":"Berger","year":"2010","journal-title":"Drug Saf"},{"key":"R27-1-20240808","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00131402-201112000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T23:14:02Z","timestamp":1723158842000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00131402-201112000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0b013e318221259d","relation":{},"ISSN":["1522-0443"],"issn-type":[{"type":"print","value":"1522-0443"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}